← Back to Screener
Mannkind Corporation (MNKD)
Price$2.75
Favorite Metrics
Price vs S&P 500 (26W)-53.07%
Price vs S&P 500 (4W)0.31%
Market Capitalization$851.90M
P/E Ratio (Annual)145.30x
All Metrics
P/CF (Annual)46.67x
Book Value / Share (Quarterly)$0.23
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)51.78%
Cash Flow / Share (Quarterly)$0.04
Price vs S&P 500 (YTD)-53.79%
Gross Margin (TTM)77.80%
Net Profit Margin (TTM)1.92%
EPS (TTM)$0.02
10-Day Avg Trading Volume3.37M
EPS Excl Extra (TTM)$0.02
Revenue Growth (5Y)39.91%
EPS (Annual)$0.02
ROI (Annual)-132.31%
Gross Margin (Annual)77.77%
Net Profit Margin (5Y Avg)-37.91%
Cash / Share (Quarterly)$0.56
P/E Basic Excl Extra (TTM)127.21x
Revenue Growth QoQ (YoY)45.82%
P/E Normalized (Annual)145.30x
ROA (Last FY)0.74%
Revenue Growth TTM (YoY)22.23%
EBITD / Share (TTM)$0.18
ROE (5Y Avg)-119.17%
Operating Margin (TTM)11.36%
Cash Flow / Share (Annual)$0.04
P/B Ratio48.40x
P/B Ratio (Quarterly)88.13x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.97x
Net Interest Coverage (TTM)1.03x
ROA (TTM)1.27%
EPS Growth QoQ (YoY)-36.95%
EV / EBITDA (TTM)24.49x
EPS Incl Extra (Annual)$0.02
Current Ratio (Annual)1.70x
Quick Ratio (Quarterly)1.41x
3-Month Avg Trading Volume5.09M
52-Week Price Return-40.17%
EV / Free Cash Flow (Annual)101.28x
P/E Incl Extra (TTM)127.21x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-0.95
P/S Ratio (Annual)2.44x
Asset Turnover (Annual)0.44x
52-Week High$6.51
Operating Margin (5Y Avg)-22.76%
EPS Excl Extra (Annual)$0.02
CapEx CAGR (5Y)-0.91%
26-Week Price Return-49.08%
Quick Ratio (Annual)1.41x
13-Week Price Return-51.99%
Total Debt / Equity (Annual)1.64x
Current Ratio (Quarterly)1.70x
Enterprise Value$1,386.36
Revenue / Share Growth (5Y)30.59%
Asset Turnover (TTM)0.66x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)0.40%
Cash / Share (Annual)$0.56
3-Month Return Std Dev90.13%
Gross Margin (5Y Avg)63.74%
Net Income / Employee (TTM)$0
ROE (Last FY)-349.48%
Net Interest Coverage (Annual)1.05x
EPS Basic Excl Extra (Annual)$0.02
P/FCF (TTM)17.01x
Receivables Turnover (TTM)6.56x
EV / Free Cash Flow (TTM)101.28x
Total Debt / Equity (Quarterly)9.95x
EPS Incl Extra (TTM)$0.02
Receivables Turnover (Annual)6.56x
ROI (TTM)-27.19%
P/S Ratio (TTM)2.44x
Pretax Margin (5Y Avg)-37.80%
Revenue / Share (Annual)$1.11
Tangible BV / Share (Annual)$-0.96
Forward P/E27.93x
Price vs S&P 500 (52W)-70.00%
P/E Ratio (TTM)127.21x
EPS Growth TTM (YoY)-78.60%
Year-to-Date Return-51.15%
5-Day Price Return8.20%
EPS Normalized (Annual)$0.02
ROA (5Y Avg)-9.91%
Net Profit Margin (Annual)1.68%
Month-to-Date Return13.06%
Cash Flow / Share (TTM)$-0.09
EBITD / Share (Annual)$0.16
Operating Margin (Annual)11.12%
LT Debt / Equity (Annual)1.64x
P/CF (TTM)46.67x
ROI (5Y Avg)-69.25%
P/E Excl Extra (TTM)127.21x
LT Debt / Equity (Quarterly)8.47x
EPS Basic Excl Extra (TTM)$0.02
P/B Ratio (Annual)4.03x
Inventory Turnover (TTM)2.45x
Pretax Margin (TTM)0.64%
Book Value / Share (Annual)$4.25
Price vs S&P 500 (13W)-52.68%
Beta1.04x
P/FCF (Annual)62.23x
Revenue / Share (TTM)$1.14
ROE (TTM)-297.71%
52-Week Low$2.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.20
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MNKDMannkind Corporation | 2.44x | 22.23% | 77.80% | — | $2.75 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
MannKind is a biopharmaceutical company commercializing therapies for cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza, an ultra rapid-acting inhaled insulin for diabetes; Furoscix, a furosemide injection for heart failure and chronic kidney disease; and V-Go, a wearable device for continuous subcutaneous insulin infusion.